Your browser doesn't support javascript.
loading
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison, Maura L; Blumenschein, George; Fayette, Jerome; Guigay, Joel; Colevas, A Dimitrios; Licitra, Lisa; Harrington, Kevin J; Kasper, Stefan; Vokes, Everett E; Even, Caroline; Worden, Francis; Saba, Nabil F; Iglesias Docampo, Lara Carmen; Haddad, Robert; Rordorf, Tamara; Kiyota, Naomi; Tahara, Makoto; Jayaprakash, Vijayvel; Wei, Li; Ferris, Robert L.
Afiliación
  • Gillison ML; Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
  • Blumenschein G; Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
  • Fayette J; Radiation Oncology Department, Centre Leon Berard, Lyon, France.
  • Guigay J; Department of Medical Oncology, Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, Nice, France.
  • Colevas AD; Department of Medicine - Med/Oncology, Stanford University, Stanford, CA, USA.
  • Licitra L; Medical Oncology Head and Neck Cancer Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.
  • Harrington KJ; Division of Radiotherapy and Imaging, Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, National Institute of Health Research Biomedical Research Centre, London, UK.
  • Kasper S; Department of Medical Oncology, West German Cancer Center, University Hospital, Essen, Germany.
  • Vokes EE; Department of Medicine, University of Chicago Medicine and Biological Sciences, Chicago, IL, USA.
  • Even C; Head and Neck Medical Oncology, Gustave Roussy, Villejuif Cedex, France.
  • Worden F; Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Saba NF; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Iglesias Docampo LC; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Haddad R; Division of Head and Neck Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
  • Rordorf T; Clinic for Medical Oncology and Hematology, Universitätsspital Zurich, Zurich, Switzerland.
  • Kiyota N; Department of Medical Oncology and Hematology, Kobe University Hospital Cancer Center, Kobe, Japan.
  • Tahara M; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Jayaprakash V; Bristol Myers Squibb, Princeton, NJ, USA.
  • Wei L; Bristol Myers Squibb, Princeton, NJ, USA.
  • Ferris RL; Department of Otolaryngology, of Immunology, and of Radiation Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
Oncologist ; 27(2): e194-e198, 2022 03 04.
Article en En | MEDLINE | ID: mdl-35641218
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nivolumab / Neoplasias de Cabeza y Cuello Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nivolumab / Neoplasias de Cabeza y Cuello Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos